Protagonist Therapeutics Debt to Equity Ratio 2015-2022 | PTGX
Current and historical debt to equity ratio values for Protagonist Therapeutics (PTGX) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Protagonist Therapeutics debt/equity for the three months ending March 31, 2022 was 0.00.
| Protagonist Therapeutics Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2022-03-31 |
$0.05B |
$0.30B |
0.15 |
| 2021-12-31 |
$0.05B |
$0.30B |
0.16 |
| 2021-09-30 |
$0.04B |
$0.33B |
0.13 |
| 2021-06-30 |
$0.05B |
$0.36B |
0.13 |
| 2021-03-31 |
$0.04B |
$0.26B |
0.15 |
| 2020-12-31 |
$0.05B |
$0.28B |
0.16 |
| 2020-09-30 |
$0.05B |
$0.17B |
0.28 |
| 2020-06-30 |
$0.06B |
$0.17B |
0.34 |
| 2020-03-31 |
$0.07B |
$0.06B |
1.15 |
| 2019-12-31 |
$0.08B |
$0.08B |
0.94 |
| 2019-09-30 |
$0.06B |
$0.10B |
0.62 |
| 2019-06-30 |
$0.06B |
$0.08B |
0.76 |
| 2019-03-31 |
$0.03B |
$0.10B |
0.31 |
| 2018-12-31 |
$0.03B |
$0.11B |
0.24 |
| 2018-09-30 |
$0.03B |
$0.12B |
0.20 |
| 2018-06-30 |
$0.03B |
$0.11B |
0.28 |
| 2018-03-31 |
$0.04B |
$0.12B |
0.30 |
| 2017-12-31 |
$0.04B |
$0.12B |
0.36 |
| 2017-09-30 |
$0.05B |
$0.06B |
0.91 |
| 2017-06-30 |
$0.01B |
$0.06B |
0.16 |
| 2017-03-31 |
$0.01B |
$0.08B |
0.10 |
| 2016-12-31 |
$0.01B |
$0.09B |
0.07 |
| 2016-09-30 |
$0.01B |
$0.10B |
0.06 |
| 2016-06-30 |
$0.07B |
$-0.05B |
-1.53 |
| 2016-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2015-12-31 |
$0.00B |
|
0.00 |
| 2015-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2015-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2014-12-31 |
$0.02B |
$-0.01B |
-1.82 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.375B |
$0.027B |
|
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
|
